VCIM
SNDX icon

Velan Capital Investment Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Velan Capital Investment Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Hold
10,000
– – 0.13% 36
2026
Q1 		$234K Sell
10,000
-120,000
-92% -$2.61M 0.15% 35
2025
Q4 		$2.73M Hold
130,000
– – 1.58% 18
2025
Q3 		$2M Buy
+130,000
New +$1.7M 1.88% 17

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Velan Capital Investment Management's SNDX Position: Q2 2026 in Review

Velan Capital Investment Management held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 10,000 shares worth $219K. The position accounts for 0.13% of the portfolio, ranked #36.

Velan Capital Investment Management first reported a position in SNDX in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.73M in Q4 2025. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Velan Capital Investment Management held 10,000 shares of Syndax Pharmaceuticals worth $219K as of Q2 2026.
  • Velan Capital Investment Management left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
  • Syndax Pharmaceuticals made up 0.13% of Velan Capital Investment Management's portfolio in Q2 2026, its #36 holding.
  • Velan Capital Investment Management first reported a position in Syndax Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Velan Capital Investment Management's Syndax Pharmaceuticals position peaked at $2.73M in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Velan Capital Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.